What is Generate Biomedicines, Inc. 's cash ratio?

Generate Biomedicines, Inc. (GENB) reported cash ratio of 2.8× in Q1 2026.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Generate Biomedicines, Inc. GENB Cash ratio

Cash ratio at other companies

MYR GroupMYRG

0.2×+0.2×

RepligenRGEN

4.6×0.0×

LKQLKQ

0.1×0.0×

Boyd GamingBYD

0.4×-0.1×

Sensata TechnologiesST

0.8×+0.1×

AppFolioAPPF

2×+1.1×

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Calculated from Generate Biomedicines, Inc. ’s reported figures.

cash and equivalents/total current liabilities=2.8×

Based on the most recent quarter.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's cash ratio?: Generate Biomedicines, Inc. (GENB) reported cash ratio of 2.8× in Q1 2026.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.